Hüsken B C, de Jong J, Beekman B, Onderwater R C, van der Vijgh W J, Bast A
Leiden/Amsterdam Center for Drug Research, Faculty of Chemistry, Vrije Universiteit, The Netherlands.
Cancer Chemother Pharmacol. 1995;37(1-2):55-62. doi: 10.1007/BF00685629.
Cancer therapy with the anthracycline doxorubicin (Dox) is limited by cardiomyopathy, which develops in animals and patients after cumulative dosing. Generation of free radicals by Dox may be involved in this cardiotoxicity. Dox binds strongly to metal ions, especially iron(III). This Dox-metal complex stimulates the generation of free radicals through self-reduction of the complex. We investigated the possibility of inhibiting Dox-induced cardiotoxicity by scavenging of free radicals and/or chelating metal ions. The effects of Dox, both alone and in combination with iron-chelating agents, were studied on inotropy of the isolated mouse left atrium, lipid peroxidation (LPO) in cardiac microsomal membranes, ferricytochrome c (cyt.c3+) reduction, and oxygen consumption. The flavonoids 7-monohydroxyethylrutoside (mono-HER) and 7,3',4'-trihydroxyethylrutoside (tri-HER) and the ethylenediaminetetraacetic acid (EDTA) analogue ICRF-198 and its precursor ICRF-187 were used as iron-chelating agents. The latter were used for comparison since ICRF-187 has been reported to inhibit the cardiotoxic effects of Dox both in vitro and in vivo. Only the flavonoids could inhibit the negative inotropic effect of Dox (35 microM) on the mouse left atrium; in the presence of tri-HER (500 microM) the beating force decreased by 18% instead of 50%, whereas mono-HER completely prevented the Dox-induced negative inotropic effect. ICRF-198 and both flavonoids (500 microM) completely inhibited Dox (35 microM)-induced LPO, whereas ICRF-187 provided 65% inhibition. The observation that both cyt.c3+ reduction and oxygen consumption induced by the Dox-iron(III) complex (50/16.6 microM Dox3Fe3+) could be inhibited by superoxide dismutase proved the involvement of superoxide anions (O2-.). The iron-chelating agents (50 microM) inhibited cyt.c3+ reduction by 91% (mono-HER), 43% (tri-HER), and 100% (ICRF-198). Only mono-HER and ICRF-198 (50 microM) were capable of inhibiting the oxygen consumption by 70% and 43%, respectively. It is concluded that flavonoids offer a good perspective for further studies on the prevention of Dox-induced cardiomyopathy.
蒽环类药物阿霉素(Dox)用于癌症治疗时会受到心肌病的限制,在动物和患者累积给药后会出现这种情况。Dox产生自由基可能与这种心脏毒性有关。Dox与金属离子,尤其是铁(III)紧密结合。这种Dox-金属复合物通过自身还原刺激自由基的产生。我们研究了通过清除自由基和/或螯合金属离子来抑制Dox诱导的心脏毒性的可能性。研究了Dox单独使用以及与铁螯合剂联合使用对分离的小鼠左心房收缩力、心脏微粒体膜脂质过氧化(LPO)、高铁细胞色素c(cyt.c3+)还原以及氧消耗的影响。黄酮类化合物7-单羟乙基芦丁(mono-HER)和7,3',4'-三羟乙基芦丁(tri-HER)以及乙二胺四乙酸(EDTA)类似物ICRF-198及其前体ICRF-187用作铁螯合剂。使用后者进行比较是因为据报道ICRF-187在体外和体内均能抑制Dox的心脏毒性作用。只有黄酮类化合物能够抑制Dox(35 microM)对小鼠左心房的负性肌力作用;在存在tri-HER(500 microM)的情况下, beating force(此处原文有误,可能是beating force,应译为“收缩力”)下降了18%而不是50%,而mono-HER完全阻止了Dox诱导的负性肌力作用。ICRF-198和两种黄酮类化合物(500 microM)完全抑制了Dox(35 microM)诱导的LPO,而ICRF-187提供了65%的抑制作用。超氧化物歧化酶能够抑制Dox-铁(III)复合物(50/16.6 microM Dox3Fe3+)诱导的cyt.c3+还原和氧消耗,这一观察结果证明了超氧阴离子(O2-.)的参与。铁螯合剂(50 microM)抑制cyt.c3+还原的程度分别为91%(mono-HER)、43%(tri-HER)和100%(ICRF-198)。只有mono-HER和ICRF-198(50 microM)能够分别抑制70%和43%的氧消耗。结论是黄酮类化合物为进一步研究预防Dox诱导的心肌病提供了良好的前景。